FDA approves TALZENNA plus XTANDI for HRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer October 28, 2026
Global Ph 2 Study of Ivonescimab in 1L Clear Cell RCC, Including Combination with Cadonilimab, initiated October 27, 2026
European Commission Approves KEYTRUDA® + Padcev® as Perioperative Treatment for Adults With Resectable MIBC October 27, 2026
NUCLIDIUM and NorthStar Enter Long-term Strategic Partnership to Advance NUCLIDIUM’s Copper-67 Radiotheranostic Oncology Pipeline October 20, 2026
Ph 3 Data Shows 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® + BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors October 20, 2026
FDA Expands ANKTIVA® Approval for BCG-Unresponsive NMIBC to Cover Both Papillary and CIS Disease October 20, 2026
EMA validates the MAA for Wevdury® (fuzuloparib) in combination with abiraterone acetate and prednisone/prednisolone for metastatic CRPC patients October 14, 2026
Carotuximab + Apalutamide Improves PFS in Interim Ph 2 Prostate Cancer trial of ENV-105 October 14, 2026
First patient dosed with LNK001 in Ph 1 study in patients with advanced or metastatic clear cell RCC October 6, 2026
Perioperative Imfinzi plus neoadjuvant enfortumab vedotin granted Priority Review in the US for MIBC patients October 1, 2026
FDA Approves WELIREG + LENVIMA for Certain Previously Treated Adult Patients With clear cell RCC October 1, 2026
Positive EU CHMP Opinion for KEYTRUDA + Padcev as Perioperative Treatment for Adults With Resectable MIBC September 22, 2026
AIM ImmunoTech Secures Broad US Patent for Rintatolimod (Ampligen®) Used in Combination with Keytruda, Expanding Oncology IP Protection for Ampligen Through 2039 September 9, 2026
FDA clears IND application for ADI-212 for the treatment of patients with metastatic CRPC September 2, 2026
First Patient Dosed in MODeFIRe-1 Ph 2 Study of MRT-2359 + Apalutamide in Patients with AR Mutation-Positive Metastatic CRPC August 25, 2026
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer July 28, 2026
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan-Tivozanib Combination for Advanced Kidney Cancer Patients July 28, 2026
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer July 28, 2026
